Dopamine toxicity involves mitochondrial complex I inhibition: Implications to dopamine-related neuropsychiatric disorders

Biochemical Pharmacology

Volumn 67, Issue 10, 2004, Pages 1965-1974

  Ben Shachar, D ^a   Zuk, R ^a   Gazawi, H ^a   Ljubuncic, P ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Brain mitochondria; Complex I; Dopamine; Neurotoxicity; Parkinson's disease; Schizophrenia

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMINE; ANTIOXIDANT; BUTYLCRESOL; CATECHOL; DOPAMINE; FERRICYANIDE; IRON DERIVATIVE; MITOCHONDRIAL COMPLEX IV; MITOCHONDRIAL COMPLEX V; MITOCHONDRIAL ENZYME; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; UBIQUINONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL LEVEL; CELL STRAIN; CHELATION; CHEMICAL STRUCTURE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; INHIBITION KINETICS; MALE; MENTAL DISEASE; MITOCHONDRION; NEUROBLASTOMA CELL; NEUROPSYCHIATRY; NEUROTOXICITY; NONHUMAN; OXIDATION; PRIORITY JOURNAL; RAT; STRUCTURE ANALYSIS;

ADENOSINE TRIPHOSPHATASES; ADENOSINE TRIPHOSPHATE; ANIMALS; DOPAMINE; ELECTRON TRANSPORT COMPLEX IV; HUMANS; MALE; MITOCHONDRIA; MITOCHONDRIAL PROTON-TRANSLOCATING ATPASES; NADH DEHYDROGENASE; NADH, NADPH OXIDOREDUCTASES; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA; TUMOR CELLS, CULTURED;

EID: 2342573633     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.02.015     Document Type: Article

References (81)

1. Weinreb O., Mandel S., Youdim M.B.H. cDNA gene expression profile homology of antioxidants and their antiapoptotic and proapoptotic activities in human neuroblastoma cells. FASEB J. 17:2003;935-937
2. Fillox F., Townsend J.J. Pre- and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection. Exp. Neurol. 119:1993;79-88
3. Ben-Shachar D., Zuk R., Glinka Y. Dopamine neurotoxicity: inhibition of mitochondrial respiration. J. Neurochem. 64:1995;718-723
4. Sirinathsinghji D.J., Heavens R.P., McBribde C.S. Dopamine-releasing action of 1-methyl-4-phenyl-1, 2, 3, 6-tetra-hydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) in the neostriatum of the rat. Brain Res. 443:1988;101-116
5. Chiueh C.C., Krishna G., Tulsi P., Obata T., Lang K., Huang S.J., et al. Intracranial microdialysis of salicylic acid to detect hydroxyl radical generation through dopamine autooxidation in the caudate nucleus: effects of MPP+. Free Radic. Biol. Med. 13:1992;581-583
6. O' Dell S.J., Weihhmuller F.B., Marshall J.F. Methamphetamine-induced dopamine terminals alteration by dopamine D1 and D2 antagonists. J. Neurochem. 60:1993;1792-1799
7. Lotharius J., O'Malley K.L. The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J. Biol. Chem. 275:2000;38581-38588
8. Rosenberg P.A. Catecholamine toxicity in cerebral cortex of dissociated cell culture. J. Neurosci. 8:1988;2887-2894
9. Michell P.P., Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in cell culture. J. Neurosci. Res. 26:1990;428-435
10. Tanaka M., Sotomatsu A., Kanai H., Hirai S. DOPA and dopamine cause cultured neuronal death in the presence of iron. J. Neurochem. 101:1991;198-203
11. Mytilineou C., Han S.K., Cohen G. Toxic and protective effects of L-DOPA on mesencephalic cell cultures. J. Neurochem. 61:1993;1470-1478
12. McLaughlin B.A., Nelson D., Erecinska M., Chesselet M.F. Toxicity of dopamine to striatal neurons in vitro and potentiation of cell death by a mitochondrial inhibitor. J. Neurochem. 70:1998;2406-2415
13. Cohen G. Oxidative stress in the nervous system. In: Sies H, editor. Oxidative stress. Academic Press: London; 1985. p. 383-401.
14. Founstedt B. Role of catechol autoxidation in the degeneration of dopamine neurons. Acta Neurol. Scand. 129:1990;12-14
15. Chiueh C.C., Miyake H., Peng M.T. Role of dopamine autoxidation, hydroxyl radical generation and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism. Adv. Neurol. 60:1993;251-258
16. Hastings T.G., Zigmond M.J. Identification of catechol-protein conjugates in neostriatal slices incubated with [3H] dopamine: impact of ascorbic acid and glutathione. J. Neurochem. 63:1994;1126-1132
17. Lee C.S., Song E.H., Park S.Y., Han E.S. Combined effect of dopamine and MPP+ on membrane permeability in mitochondria and cell viability in PC12 cells. Neurochem. Int. 43:2003;147-154
18. Loeffler D.A., DeMaggio A.J., Juneau P.L., Havaich M.K., LeWitt P.A. Effects of enhanced dopamine turnover in vivo on glutathione oxidation. Clin. Neuropharmacol. 17:1994;370-379
19. Ziv I., Melamed E., Nardi N., Luria D., Achiron A., Offen D., et al. Dopamine induced apoptosis-like cell death in cultured chick sympathetic neurons - a possible novel pathogenetic mechanism in Parkinson's disease. Neurosci. Lett. 170:1994;136-140
20. Gabbay M., Tauber M., Porat S., Simantov R. Selective role of glutathione in protecting human neuronal cells from dopamine-induced apoptosis. Neuropharmacology. 35:1996;571-578
21. Simantov R., Blinder E., Ratovitski T., Tauber M., Gabbay M., Porat S. Dopamine induced apoptosis in human neural cells: inhibition by nucleic acid antisense to the dopamine transporter. J. Neurosci. 74:1996;39-50
22. Massenaro J.M., Gong L., Kuage H., Baker I., Wyatt R.J. Dopamine induces apoptotic cell death of cathecolaninergic cell line derived from the central nervous system. Mol. Pharmacol. 50:1996;1309-1315
23. Offen D., Ziv I., Panet H., Wasserman L., Stein R., Melamed E., et al. Dopamine-induced apoptosis is inhibited in PC12 cells expressing bcl-2. Cell Mol. Neurobiol. 17:1996;289-304
24. Beal M.F. Does impairment of energy metabolism result in cytotoxic neuronal death in neurodegenerative illnesses? Ann. Neurol. 31:1992;119-130
25. Beal M.F. Aging energy and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38:1995;357-366
26. Cavalier L., Jazin E., Eriksson I., Prince J., Bave B., Oreland L., et al. Decreased cytochrome c oxidase activity and lack age related accumulation of mtDNA in brain of schizophrenics. Genomics. 29:1995;217-228
27. Whatley S.A., Curi D., Marchbanks R.M. Mitochondrial involvement in schizophrenia and other functional psychoses. Neurochem. Res. 21:1996;995-1004
28. Ben-Shachar D., Zuk R., Gazawi H., Reshef A., Sheinkman A., Klein E. Increased mitochondrial complex I activity in platelets of schizophrenic patients. Int. J. Neuropsychopharmacol. 2:1999;245-253
29. Ben-Shachar D. Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine. J. Neurochem. 83:2002;1241-1251
30. Kingsbury A.E., Cooper M., Schapira A.H., Foster O.J. Metabolic enzyme expression in dopaminergic neurons in Parkinson's disease: an in situ hybridization study. Ann. Neurol. 50:2000;142-149
31. Kato T., Kato N. Mitochondrial dysfunction in bipolar disorder. Bipolar Disord. 2:2000;180-190
32. Dror N., Karry R., Mazor M., Sheinkman A., Klein E., Ben-Shachar D. State dependent alterations in mitochondrial complex I activity in platelets: a potential peripheral marker for schizophrenia. Mol. Psychiatry. 7:2002;995-1001
33. Przedborski S., Jackson-Lewis V., Muthane U., Jiang H., Ferreria M., Naini A.B., et al. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann. Neurol. 34:1993;715-723
34. Chan P., Di Monte D.A., Luo J.J., DeLanney L.E., Irwin I., Langston J.W. Rapid ATP loss caused by methamphetamine in the mouse striatum: relationship between energy impairment and dopaminergic neurotoxicity. J. Neurochem. 62:1994;2484-2487
35. Royland J.E., Delfani K., Langston J.W., Janson A.M., Di Monte D.A. 7-Nitroindazole prevents 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced ATP loss in the mouse striatum. Brain Res. 839:1999;41-48
36. Cohen G., Farooqui R., Kesler N. Parkinson's Disease: a new link between monoamine oxidase and mitochondrial electron flow. Proc. Natl. Acad. Sci. U.S.A. 94:1997;4890-4894
37. Ramsay R.R., Salach J.I., Singer T.P. Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+. Biochem. Biophys. Res. Commun. 134:1986;743-748
38. Nicklas W.J., Vyas I., Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine. Life Sci. 36:1985;2503-2508
39. Mizuno Y., Saitoh T., Sone N. Inhibition of mitochondrial NADH-ubiquinone oxidoreductase activity by 1-methyl-4-phenylpyridinium ion. Biochem. Biophys. Res. Commun. 143:1987;294-299
40. Glinka Y., Youdim M.B.H. Inhibition of mitochondrial complex I and IV by 6-hydroxydopamine. Eur. J. Pharmacol. 292:1995;329-332
41. Dabbeni-Sala F., Di Santo S., Franceschini D., Skaper S.D., Giusti P. Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. FASEB J. 15:2001;164-170
42. Berman S.B., Hatings T.G. Dopamine oxidation alters mitochondrial respiration and induces transition in brain mitochondria: Implications for Parkinson's disease. J. Neurochem. 73:1999;1127-1137
43. Ben-Shachar D., Klein E., Tabak A., Finberg J.P.M. Effect of single and repeated ministration of fluvoxamine on noradrenaline release in rat brain. Eur. J. Pharmacol. 332:1997;237-242
44. Sims N.R. Rapid isolation of metabolically active mitochondria from rat brain and subregions using percoll density gradient centrifugation. J. Neurochem. 55:1990;698-707
45. Ragan CI, Wilson MT, Darley-Usmar VM, Lowe PN. Subfractionation of mitochondria and isolation of the proteins of oxidative phosphorylation. In: Darely-Usmar VM, Rickwood D, Wilson M, editors. Mitochondria, a practical approach. London: IRL Press; 1987. p. 79-112.
46. Hatefi Y. Preparation and properties of the enzyme complexes of the mitochondrial oxidative phosphorylation system. Methods Enzymol. 53:1978;3-10
47. Krige D., Carroll M.T., Cooper J.M., Maesden C.D., Schapira A.H.V. Platelet mitochondrial function in Parkinson's disease. Ann. Neurol. 32:1992;782-788
48. Estornell E., Fato R., Pallotti F., Lenaz G. Assay conditions for the mitochondrial NADH:coenzyme Q oxidoreductase. FEBS. 332:1993;127-130
49. Singer TP. Determination of the activity of succinate, NADH, choline and glycerophosphate dehydrogenases. In: Glick E, editor. Methods of biochemical analysis, vol. 22. NY: Inter. Science; 1974. p. 123-175.
50. +-ATPase/ATPsynthase and the pattern of membrane fatty acid composition. Biochim Biophys Acta. 1141:1993;90-94
51. Storrie B., Madden E.A. Isolation of subcellular organelles. Methods Enzymol. 182:1990;203-225
52. Fiske C.H., Subbarow Y.J. The calorimetric determination of phosphorus. Biol. Chem. 66:1925;375-381
53. Nagamune H., Fukushima Y., Takada J., Yoshida K., Unami A., Shimooka T., et al. The lipophilic weak base Au-1421 is a potent protonophore type cationic uncoupler of oxidative phosphorylation in mitochondria. Biochim. Biophys. Acta. 1141:1993;231-237
54. Graham D.G. Catecholamine toxicity: a proposal for molecular pathogenesis of manganese neurotoxicity in Parkinson's disease. Neurotoxicology. 5:1984;38-96
55. Ben-Shachar D., Riederer P., Youdim M.B.H. Iron melanin interaction and lipid peroxidation: implication for Parkinson's disease. J. Neurochem. 57:1991;1609-1614
56. Simpson P.B., Russell J.T. Role of mitochondrial Ca2+ regulation in neuronal and glial cell signaling. Brain Res. Rev. 26:1997;72-81
57. Babcock D.F., Hill B. Mitochondrial oversight of cellular Ca2+ signaling. Curr. Opin. Neurobiol. 8:1998;398-404
58. Green D.R., Reed J.C. Mitochondria and apoptosis. Science. 281:1998;1309-1312
59. Wallace D.C. Mitochondrial diseases in man and mouse. Science. 283:1999;1482-1488
60. Gomez-Santos C., Ferrer I., Santidrian A.F., Barrachina M., Gil J., Ambrosio S. Dopamine induces autophagic cell death and alpha-synuclein increase in human neuroblastoma SH-SY5Y cells. J. Neurosci. Res. 73:2003;41-50
61. Bloom F.E., Algeria S., Groppetti A., Revuelta A., Costa E. Lesions of central norepinephrine terminals with 6-OH-dopamine: biochemistry and fine structure. Science. 166(910):1969;1284-1286
62. Javitch J.A., D'Amato R.J., Strittmatter S.M., Snyder S.H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. USA. 82:1985;2173-2177
63. Morikawa N., Nakagawa-Hattori Y., Mizuno Y. Effect of dopamine, dimethoxyphenylethylamine, papaverine, and related compounds on mitochondrial respiration and complex I activity. J. Neurochem. 66:1996;1174-1181
64. Jenner P. Oxidative stress in Parkinson's disease. Ann. Neurol. 53:2003;S26-S38
65. Lusty C.J., Machinist J.M., Singer T.P. Studies on the respiratory chain-linked nicotinamide adenine dinucleotide dehydrogenase. VII. Labile sulfide group in the dehydrogenase and related proteins. J. Biol. Chem. 240:1965;1804-1810
66. Gutman M., Singer T.P. EPR studies on the iron sulfur centers of DPNH dehydrogenase during redox cycle of the enzyme. Biochem. Biophys. Res. Commun. 44:1973;1572-1578
67. Singer T.P. Mitochondrial electron transport inhibitors. Methods Enzymol. 55:1979;454-462
68. Singer T.P., Ramsay R.R. The reaction site of rotenone and ubiquinone with mitochondrial NADH dehydrogenase. Biochim. Biophys. Acta. 1187:1994;198-202
69. Gluck M.R., Krueger M.J., Ramsay R.R., Sablin S.O., Singer T.P., Nicklas W.J. Characterization of the inhibitory mechanism of 1-methyl-4-phenylpyridinium and 4-phenylpyridine analogs in inner membrane preparations. J. Biol. Chem. 269:1994;3167-3174
70. Harmon H.J., Crane F.L. Inhibition of mitochondrial electron transport by hydrophilic metal chelators. Determination of dehydrogenase topography. Biochim. Biophys. Acta. 440:1976;45-48
71. Joyce P.I., Atcheson R., Marcus R.J., Heffernan A.M., Rowbotham D.J., Lambert D.G. Interaction of local anaesthetic agents with the endogenous norepinephrine transporter in SH-SY5Y human neuroblastoma cells. Neurosci. Lett. 305:2001;161-164
72. Zarow C., Lyness S.A., Mortimer J.A., Chui H.C. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol. 60:2003;337-341
73. Schapira A.H.V., Cooper J.M., Dexter D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54:1990;823-827
74. Singer T.P., Ramsay R.R., Ackrell B.A. Deficiencies of NADH and succinate dehydrogenases in degenerative diseases and myopathies. Biochim. Biophys. Acta. 1271:1995;211-219
75. Burkhardt C., Kelly J.P., Lim Y.H., Filley C.M., Parker W.D. Neuroleptic Medications inhibit complex I of the electron transport chain. Ann. Neurol. 33:1993;512-517
76. Maurer I., Moller H.J. Inhibition of complex I by neuroleptics in normal human brain cortex paralles the extrapyramidal toxicity of neuroleptics. Mol. Cell Biochem. 174:1997;255-259
77. Greenamyre J.T., Sherer T.B., Betarbet R., Panov A.V. Complex I and Parkinson's disease. IUBMB Life. 52:2001;135-141
78. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1983;979-980
79. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3:2000;1301-1306
80. Hornykiewicz O., Kish S.J. Biochemical pathophysiology of Parkinson's disease. Adv. Neurol. 45:1987;19-34
81. Parkinson's Disease Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-83.